Company Presentation
Summary by AI BETAClose X
24 June 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Company Presentation
Coiled Therapeutics (AIM: COIL) (OTCQB: COTFX), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that ahead of its presentation at the Proactive One2One Investor Forum in London at 6pm BST today, the presentation is available to download from the Coiled Therapeutics website at https://coiledplc.com/investors/results-reports.
The Forum will be hosted at The Chesterfield Mayfair, 35 Charles Street, London, W1J 5EB.
In order to register for the event, please use the following link:
https://www.proactiveinvestors.co.uk/register/event_details/470
-Ends-
Enquiries:
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO) |
Via Burson Buchanan
|
|
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
|
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Joint Broker) Damon Heath
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino
|
+44 (0)20 4530 6926
+61 (0)8 9223 2222
|
|
Burson Buchanan (Public Relations) Henry Harrison Topham / Jamie Hooper / Toto Berger |
+44 (0)20 7466 5000
|
|
|
|
|
Harbor Access (US Investor Relations) Matt Kelly / Jonathan Paterson |
+1 475 477 9404 |
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.
By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.
The asset is currently being evaluated in an ongoing Phase I open-label dose-escalation study. The Company plans to initiate dose-expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 minutes ago Bioventix
- 15 minutes ago NATWEST GROUP
- 20 minutes ago CLS Holdings
- 36 minutes ago Metals Exploration
- 45 minutes ago QinetiQ Group